US Patent Issued to Biohaven Therapeutics on Aug. 12 for "Use of glutamate modulating agents with immunotherapies to treat cancer" (Connecticut Inventor)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,383,619, issued on Aug. 12, was assigned to Biohaven Therapeutics Ltd. (Tortola, British Virgin Islands).

"Use of glutamate modulating agents with immunotherapies to treat cancer" was invented by Vladimir Coric (Madison, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed."

The patent was filed on May 19...